<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00767624</url>
  </required_header>
  <id_info>
    <org_study_id>SU-08132008-1277</org_study_id>
    <secondary_id>MH78924</secondary_id>
    <nct_id>NCT00767624</nct_id>
  </id_info>
  <brief_title>TRIAD - Treatment of Insomnia and Depression</brief_title>
  <official_title>Improving Depression Outcome by Adding Insomnia Therapy to Antidepressants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the proposed three-site study is to increase the rate of full remission from major
      depressive disorder (MDD) at the end of 16 weeks of treatment for people who experience both
      major depressive disorder and insomnia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants with major depressive disorder and insomnia who meet all study criteria will
      receive state-of-the-art antidepressant medications and one of two insomnia therapies. The
      specific therapy for insomnia will be determined by chance (like a flip of a coin), with an
      equal chance to receive either cognitive-behavioral therapy for insomnia or desensitization
      psychotherapy for insomnia. The study physician will select an initial antidepressant
      medication from a list of three possible medications . If that medication is not helpful,
      another medication may be tried after 8 weeks or in the event of severe side effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Participants With Depression Remission</measure>
    <time_frame>16 weeks</time_frame>
    <description>Depression remission was defined if both a and b below are satisfied
absence of both depressed mood and anhedonia for at least three consecutive weeks
no more than two other diagnostic criterion symptoms of depression met for at least three consecutive weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Insomnia Remission</measure>
    <time_frame>16 weeks</time_frame>
    <description>Remission was defined as endpoint ISI&lt;8. The ISI scale score ranges from 0 to 28 with lower scores representing less severe insomnia. A score of 0-7 is interpreted as absence of insomnia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Sleep Initiation and Maintenance Disorders</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>antidepressant + desensitization</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Combined antidepressant medication (determined by an algorithm) plus desensitization therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>antidepressant + cognitive behavioral</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Combined antidepressant medication (determined by algorithm) plus cognitive behavioral therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antidepressant</intervention_name>
    <description>Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance</description>
    <arm_group_label>antidepressant + desensitization</arm_group_label>
    <arm_group_label>antidepressant + cognitive behavioral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Desensitization Therapy for Insomnia</intervention_name>
    <arm_group_label>antidepressant + desensitization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Behavioral Therapy for Insomnia</intervention_name>
    <arm_group_label>antidepressant + cognitive behavioral</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Meets criteria for Major Depressive Disorder

          2. Between 18 and 75 years of age and adequately fluent in English

          3. Meets criteria for an insomnia disorder

        Exclusion Criteria:

          1. Women who are currently pregnant, breast-feeding, or not using a reliable birth
             control method.

          2. People for whom the antidepressant medication(s) provided in the study is not
             indicated

          3. People who have had minimum adequate trials of (or have not been able to tolerate) all
             three study medications.

          4. People with uncontrolled medical conditions.

          5. People with moderate or severe sleep disorders other than insomnia

          6. Individuals on a fixed night shift or rotating work schedule that requires a night
             shift.

          7. Patients with a current principal diagnosis of a psychiatric disorder that
             necessitates treatment that is not offered in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachel Manber</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2008</study_first_submitted>
  <study_first_submitted_qc>October 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2008</study_first_posted>
  <results_first_submitted>August 5, 2016</results_first_submitted>
  <results_first_submitted_qc>October 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 5, 2016</results_first_posted>
  <last_update_submitted>October 10, 2016</last_update_submitted>
  <last_update_submitted_qc>October 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Rachel Manber</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Antidepressant + Desensitization</title>
          <description>Combined antidepressant medication (determined by an algorithm) plus desensitization therapy
Antidepressant: Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance
Desensitization Therapy for Insomnia</description>
        </group>
        <group group_id="P2">
          <title>Antidepressant + Cognitive Behavioral</title>
          <description>Combined antidepressant medication (determined by algorithm) plus cognitive behavioral therapy
Antidepressant: Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance
Cognitive Behavioral Therapy for Insomnia</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to treat</population>
      <group_list>
        <group group_id="B1">
          <title>Antidepressant + Desensitization</title>
          <description>Combined antidepressant medication (determined by an algorithm) plus desensitization therapy
Antidepressant: Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance
Desensitization Therapy for Insomnia</description>
        </group>
        <group group_id="B2">
          <title>Antidepressant + Cognitive Behavioral</title>
          <description>Combined antidepressant medication (determined by algorithm) plus cognitive behavioral therapy
Antidepressant: Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance
Cognitive Behavioral Therapy for Insomnia</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
            <count group_id="B2" value="75"/>
            <count group_id="B3" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.0" spread="12.3"/>
                    <measurement group_id="B2" value="48.3" spread="12.7"/>
                    <measurement group_id="B3" value="46.6" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insomnia Severity Index (ISI)</title>
          <description>The ISI is a 7-item self-report questionnaire assessing the nature, severity, and impact of insomnia. A 5-point Likert scale is used to rate each item (e.g., 0 = no problem; 4 = very severe problem), yielding a total score ranging from 0 to 28, with larger numbers representing greater severity. The total score is interpreted as follows: absence of insomnia (0-7); sub-threshold insomnia (8- 14); moderate insomnia (15-21); and severe insomnia (22-28).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.3" spread="3.9"/>
                    <measurement group_id="B2" value="19.4" spread="4.3"/>
                    <measurement group_id="B3" value="18.9" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hamilton Rating Scale for Depression (HRSD)</title>
          <description>The HRSD is a 17-item semi-structured interview assessing the severity of depression in the past week. Items are rated on a 3 or 5 point scale. The total score is the sum of individual items, yielding a total score ranging from 0 to 52, with larger numbers representing greater severity. The total score is interpreted as follows: absence of depression (0-7); mild depression (8- 16); moderate depression (17-23); and severe depression (24-52).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.5" spread="3.7"/>
                    <measurement group_id="B2" value="21.9" spread="3.8"/>
                    <measurement group_id="B3" value="21.7" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants With Depression Remission</title>
        <description>Depression remission was defined if both a and b below are satisfied
absence of both depressed mood and anhedonia for at least three consecutive weeks
no more than two other diagnostic criterion symptoms of depression met for at least three consecutive weeks</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Antidepressant + Desensitization</title>
            <description>Combined antidepressant medication (determined by an algorithm) plus desensitization therapy
Antidepressant: Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance
Desensitization Therapy for Insomnia</description>
          </group>
          <group group_id="O2">
            <title>Antidepressant + Cognitive Behavioral</title>
            <description>Combined antidepressant medication (determined by algorithm) plus cognitive behavioral therapy
Antidepressant: Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance
Cognitive Behavioral Therapy for Insomnia</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Depression Remission</title>
          <description>Depression remission was defined if both a and b below are satisfied
absence of both depressed mood and anhedonia for at least three consecutive weeks
no more than two other diagnostic criterion symptoms of depression met for at least three consecutive weeks</description>
          <units>percentage of participants in arm</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.0"/>
                    <measurement group_id="O2" value="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in Insomnia Remission</title>
        <description>Remission was defined as endpoint ISI&lt;8. The ISI scale score ranges from 0 to 28 with lower scores representing less severe insomnia. A score of 0-7 is interpreted as absence of insomnia.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Antidepressant + Desensitization</title>
            <description>Combined antidepressant medication (determined by an algorithm) plus desensitization therapy
Antidepressant: Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance
Desensitization Therapy for Insomnia</description>
          </group>
          <group group_id="O2">
            <title>Antidepressant + Cognitive Behavioral</title>
            <description>Combined antidepressant medication (determined by algorithm) plus cognitive behavioral therapy
Antidepressant: Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance
Cognitive Behavioral Therapy for Insomnia</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Insomnia Remission</title>
          <description>Remission was defined as endpoint ISI&lt;8. The ISI scale score ranges from 0 to 28 with lower scores representing less severe insomnia. A score of 0-7 is interpreted as absence of insomnia.</description>
          <units>percentage of particpants in arm</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Antidepressant + Desensitization</title>
          <description>Combined antidepressant medication (determined by an algorithm) plus desensitization therapy
Antidepressant: Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance
Desensitization Therapy for Insomnia</description>
        </group>
        <group group_id="E2">
          <title>Antidepressant + Cognitive Behavioral</title>
          <description>Combined antidepressant medication (determined by algorithm) plus cognitive behavioral therapy
Antidepressant: Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance
Cognitive Behavioral Therapy for Insomnia</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma R side abdomen</sub_title>
                <description>Medical event requiring hospitalization The person experiencing this event had another SAE event</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening of known cardiac condition</sub_title>
                <description>Medical event requiring hospitalization . Event was not expected and was not related to study meds</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Chest pain in a patient with CAD</sub_title>
                <description>Medical event requiring hospitalization</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>suicidal ideation and worsening depression</sub_title>
                <description>Psychiatric event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Severe vaginal bleeding and pain</sub_title>
                <description>Medical event requiring hospitalization.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <description>Medical event requiring hospitalization The person experiencing this event had another serious adverse event</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Medically significant event not requiring hospitalization</sub_title>
                <description>slipped on street curb and broke wrist</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Our results do not inform clinical guidelines for any single antidepressant medication.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Rachel Manber, PhD</name_or_title>
      <organization>STANFORD UNIVERSITY</organization>
      <phone>6504981266</phone>
      <email>rmanber@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

